Revlimid (Lenalidomide Capsules)
- Medicine Name: Revlimid
- API: Lenalidomide
- Dosage Form & Strength: Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg
- Manufactured By: Celgene Corporation
Revlimid (lenalidomide capsule) is a thalidomide analogue used for the treatment of adult patients with:
- Multiple myeloma (MM), in combination with dexamethasone
- MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
- Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
- Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
- Previously treated follicular lymphoma (FL), in combination with a rituximab product
- Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.
Limitations of Use: This therapeutic drug is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Recommended Dosage:
Recommended Dosage for Multiple Myeloma (MM): The recommended starting dose of Lenalidomide is 25 mg taken orally once daily on Days 1 to 21 of repeated 28-day cycles along with dexamethasone. For patients greater than 75 years old, the starting dose of dexamethasone may be reduced.
Recommended Dosage for Multiple Myeloma (MM), as following auto-HSCT: Initiate Lenalidomide maintenance therapy after adequate hematologic recovery (ANC at least 1,000/mcL and/or platelet counts at least 75,000/mcL). The recommended starting dose is 10 mg once daily continuously (Days 1 to 28 of repeated 28-day cycles) until there is evidence of disease progression or unacceptable toxicity. After three cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.
Recommended Dosage for Myelodysplastic Syndromes (MDS): The recommended starting dose of Lenalidomide is 10 mg daily. Treatment is continued or modified based on clinical and laboratory findings. Continue treatment until there is evidence of disease progression or unacceptable toxicity.
Recommended Dosage for Mantle Cell Lymphoma (MCL): The recommended starting dose of Lenalidomide is 25 mg/day orally on Days 1 to 21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma. Treatment should be continued until there is evidence of disease progression or unacceptable toxicity. Treatment is continued, modified, or discontinued based on clinical and laboratory findings.
Recommended Dosage for Follicular Lymphoma or Marginal Zone Lymphoma: The recommended starting dose of Lenalidomide is 20 mg taken orally once daily on Days 1 to 21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with a rituximab product.
- Lenalidomide capsules can cause severe birth defects or the death of an unborn baby. Women of childbearing potential must use two forms of contraception and undergo regular pregnancy testing before and during treatment
- Treatment with Lenalidomide can cause significant decreases in blood cell counts (neutropenia, thrombocytopenia). Regular blood tests are necessary to monitor blood counts during treatment.
- Patients taking this therapeutic drug have an increased risk of developing blood clots (deep vein thrombosis and pulmonary embolism). Prophylactic anticoagulation may be considered based on individual risk factors.
- Treatment with this medication may cause liver function abnormalities, including hepatotoxicity. Liver function should be monitored regularly during treatment.
- There is an increased risk of developing secondary primary malignancies in patients treated with Revlimid, especially when combined with other anti-cancer therapies. Regular monitoring and appropriate cancer screenings are recommended.
- Serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Discontinue treatment if severe skin reactions occur.
- TLS, a potentially life-threatening condition, can occur, particularly in patients with high tumor burden. Appropriate prophylaxis and monitoring are necessary.
- Hypersensitivity reactions, including angioedema and anaphylaxis, can occur. Immediate medical attention is required if these reactions develop.
- This medicinal product can affect thyroid function, leading to hypothyroidism or hyperthyroidism. Regular thyroid function tests are recommended.
What documents are required to import REVLIMID to India?
REVLIMID (lenalidomide) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
REVLIMID (lenalidomide capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
- IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Revlimid in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of REVLIMID (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Revlimid prices in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source REVLIMID (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Revlimid®?
Lenalidomide is a Generic Name for the trade name drug Revlimid®.
What is the Manufacturer’s Name of Revlimid®?
Revlimid® is manufactured by Celgene Corporation.
Is Revlimid® approved by the FDA?
Yes, Revlimid® is approved by the FDA. Date of first approval: December 27, 2005.
What is the dosage and form of Revlimid® supplied?
Revlimid® is supplied as Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg for oral administration.
How much does Revlimid® cost in India?
Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Revlimid in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Revlimid®?
Store Revlimid at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly closed container away from light.
Is it safe to buy Revlimid® online in India?
Yes, one can buy Revlimid online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Revlimid® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.